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Background: Although both excision repair cross-complementing group 1 (ERCC1) and breast cancer susceptibility
gene 1 (BRCA1) can be effective biomarkers for chemosensitivity in primary malignant tumors, their applicability to
metastases is poorly understood. Here, ERCC1 and BRCA1, which are linked to lymph node metastasis (LNM) in
colorectal cancer (CRC), were evaluated in primary CRC samples from Chinese patients with LNM (LNM CRC) or
without LNM (non-LNM CRC). mRNA levels of ERCC1 and BRCA1 in CRC samples, and their relationships to primary
CRC and LNM, were also examined.
Methods: Differences in BRCA1 and ERCC1 gene expression between primary CRC with or without LNM were
assessed in CRC samples from 120 Chinese patients, using real-time polymerase chain reaction. Relationships
between ERCC1 and BRCA1 expression and clinicopathological parameters and prognoses were also examined.
Results: ERCC1 and BRCA1 were significantly down-regulated in LNM CRC compared with non-LNM CRC. Down-
expression of ERCC1 and BRCA1 was significantly associated with LNM (P < 0.001), advanced TNM stage (P < 0.001),
and decreased 5-year overall survival rate (P < 0.001). Univariate and multivariate analyses showed ERCC1 and
BRCA1 expression as independent predictors of recurrence and survival in CRC patients (P < 0.05).
Conclusions: ERCC1 and BRCA1 mRNA expression levels correlate inversely to CRC metastasis. ERCC1 and BRCA1
might serve as biomarkers for LNM and as prognostic indicators for CRC; their down-expressions are predictors of
poor outcome in CRC patients.
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The incidence of colorectal cancer (CRC) is higher in the
United States than in China, where it is the third leading
cause of cancer-related death in both sexes. However, its
rate in China has increased steeply in recent years. Most
Chinese patients with CRC have metastatic disease at
diagnosis; earlier detection of their disease would greatly
improve their odds of survival [1]. Although recent
advances in chemotherapy have prolonged survival of
patients with advanced disease, these treatments are* Correspondence: bobojpn@hotmail.com
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distribution, and reproduction in any mediumhandicapped by the lack of early-presenting biomarkers
for CRC metastasis. Exploration of candidate genes to
establish potent biomarkers for earlier detection of lymph
node metastasis (LNM) would permit adoption of more
suitable chemotherapeutic regimens, although prognoses
of patients with CRC are also affected by such factors as
tumor localization, quality of surgical procedures, gender,
age, and patient’s overall performance status. Monitoring
of high-risk individuals increases their 5-year survival rate
and decreases chances of cumulative recurrence.
The excision repair cross-complementing group 1 gene
(ERCC1) is an essential member of the nucleotide excision
repair (NER) pathway, which accounts for most plat-
inum–DNA adduct repairs. ERCC1 has been established
as a useful molecular marker for NER activity. Early stud-
ies have shown that higher ERCC1 mRNA levels aretral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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various tissues [2]. Interestingly, ERCC1 expression is also
associated with cellular and clinical resistance to platinum
compounds and to platinum-based chemotherapy, includ-
ing those for lung and gastric malignancies [3,4].
Breast cancer susceptibility gene 1 (BRCA1) is an essen-
tial component of several DNA-repair pathways that affect
homologous recombination repair, non-homologous
repair and NER. BRCA1 is considered to be a differential
modulator of tumor response to cisplatin and taxanes
[5-7], and BRCA1 levels are reportedly associated with
chemosensitivity to cisplatin [8] and taxanes [9,10].
Although the aforementioned studies suggest that
both ERCC1 and BRCA1 are effective biomarkers for
chemosensitivity in primary tumors, information on their
expression in metastases is limited. Therefore, we ex-
plored the applicability of these biomarkers as predictive
factors in CRC metastasis.
The current study is thus designed to investigate the
possibility of using ERCC1 and BRCA1 as biomarkers in
CRC metastatic specimens from Chinese patients. We
examined mRNA levels of ERCC1 and BRCA1 in CRC
with LNM (LNM CRC) or without LNM (non-LNM
CRC), using real-time quantitative polymerase chain re-
action (RT-PCR). We also verified the relationship of
ERCC1 and BRCA1 levels on prognosis in CRC patients.
Methods
Patient population and characteristics of tissue samples
Samples from a total of 120 patients with colorectal car-
cinoma were collected from surgical resections performed
in our hospital (Fudan University Shanghai Cancer Center,
Shanghai, China), after obtaining informed consent. None
of the patients received chemotherapy or radiotherapy
before surgery. Resected specimens were reviewed by
two senior pathologists according to the criteria de-
scribed in the American Joint Committee on Cancer’s
Cancer Staging Manual (7th edition, 2010) [11]. At
least 12 lymph nodes each were retrieved from patients
with non-LNM CRC, none of whom had distant metas-
tasis. The fresh colorectal tumor tissues were obtained
immediately after surgery, washed twice with chilled
phosphate-buffered saline (PBS), immediately stored in
liquid nitrogen and at –80°C in our tissue bank until
further use. Ethical approval was obtained from the
Cancer Center Research Ethics Committee of Fudan
University.
Gene expression analysis by real-time quantitative PCR
ERCC1 and BRCA1 gene expression was assessed in SYBR
Green Supermix (Promega). Samples were treated using a
laser capture microdissection technique (Palm Microlaser,
Oberlensheim, Germany) to ensure a minimum of 80% of
tumor tissue. RNA was then extracted with phenol-chloroform-isoamyl alcohol, followed by precipitation with
isopropanol in the presence of glycogen and sodium
acetate, resuspension in diethyl pyrocarbonate water
(Ambion Inc., Austin, TX), and treatment with DNAse I
(Ambion Inc., Austin, TX) to avoid DNA contamination.
Complementary DNA was synthesized using Maloney
Murine Leukemia Virus retrotranscriptase enzyme. Tem-
plate cDNA was added to Taqman Universal Master Mix
(AB, Applied Biosystems, Foster City, CA) in a 12.5-μl
reaction with specific primers and probe for each gene.
Primer and probe sets were designed using Primer Express
2.0 Software (AB) and RefSeq sequences (http://www.ncbi.
clm.cih.gob/gene). Quantification of gene expression was
carried out using the ABI Prism 7900HT Sequence Detec-
tion System (AB).
Relative gene expression quantification was calculated
according to the comparative cycle threshold (Ct)
method [12] using β-actin as an endogenous control and
commercial RNA controls (Stratagene, La Jolla, CA) as
calibrators. Final results were determined as follows:
2– (ΔCt sample – ΔCt calibrator), where ΔCt values of the
calibrator and sample are determined by subtracting the
Ct value of the target gene from the value of the β-actin
gene. In all experiments, only triplicates with a standard
deviation of the Ct value < 0.20 were accepted. In addition,
for each sample analyzed, a retrotranscriptase minus con-
trol was run in the same plate to assure lack of genomic
DNA contamination.
Western blotting
Briefly, 30-μg protein samples from each case were sepa-
rated by 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis and subsequently transferred to poly
(vinylidene fluoride) membranes. The membranes were
incubated with rabbit polyclonal antibody against ERCC1
or BRCA1 (1:1000 dilution; Abcam, Cambridge, UK) and
then incubated with a horseradish-peroxidase-conjugated
secondary antibody (1:100 dilution; Proteintech, Chicago,
IL, USA). β-Actin was detected simultaneously as a load-
ing control (anti-β-actin, 1:1000 dilution; Kangchen,
Beijing, China). All blots were visualized using an ECL
detection system (Amersham, Arlington Heights, IL,
USA) and quantitated by densitometry using an LAS-
3000 imager.
Immunohistochemistry
Both ERCC1 and BRCA1 expression were examined
immunohistochemically using paraffin-embedded tissues.
In brief, 4-μm-thick tissue sections were heated in 6.5 -
mmol/L citrate buffer (pH 6.0) at 100°C for 28 min, and in-
cubated with antibodies against ERCC1 or BRCA1 (1:200
dilution). Immunostaining was performed using the DAKO
En-Vision System (Dako Diagnostics, Zug, Switzerland). In
the negative control group, PBS was used instead of
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pendent experienced pathologists. Each sample was
graded according to intensity and extent of staining.
The intensity of staining was scored as 0 (no staining),
1 (weak staining), and 2 (strong staining). The extent of
staining was based on the percentage of positive tumor
cells: 0 (no staining), 1 (1–25%), 2 (26–50%), 3 (51–75%),
and 4 (76–100%). These two scores were added together
for a final score. The case was considered negative if the
final score was 0 or 1 (−) or 2 or 3 (±), and positive if the
score was 4 or 5 (+) or 6 or 7 (++). In most cases, the
two reviewers provided consistent results. Any inconsist-
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Figure 1 Confirmation of the overexpression of BRCA1 and ERCC1 inStatistical analysis
The PCR analysis results were expressed as ratios be-
tween two absolute measurements (gene of interest/ in-
ternal reference gene). Student’s t test was used to
evaluate differences in ERCC1 and BRCA1 expression
between LNM CRC and non-LNM CRC. The χ2 test was
used to assess relationships between ERCC1 and BRCA1
expression and clinicopathological factors. The cumula-
tive recurrence and survival probability were estimated
using the Kaplan–Meier method; differences were calcu-
lated by log-rank test. Prognostic factors were deter-
mined using Cox regression analysis. Recurrence-free
and overall survival times were calculated from the first
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http://www.biomedcentral.com/1471-2407/13/103recurrence or to death from any cause, respectively. The
diagnosis of recurrence was based on the typical features
presented on computed tomography/magnetic resonance
imaging and elevated serum carcinoembryonic anti-
gen. All P values were two-sided; P < 0.05 was consid-
ered to be significant. Statistical analyses used SPSS
13.0 software.Table 2 ERCC1 expression and relationship with
clinicopathological factors in CRCResults
Confirmation of ERCC1 and BRCA1 expression in non-
LNM and LNM CRC specimens
Real-time quantitative PCR was used to analyze ERCC1
and BRCA1 expression in different groups of CRC. Relative
gene expression quantifications were calculated according
to the comparative Ctmethod using β-actin as an endogen-
ous control. Median ERCC1 mRNA expression was 6.6 in
non-LNM CRC (range: 2.8–8.52; n = 60) and 3.4 in LNM
CRC (range: 2.2–8.16; n = 60). Median BRCA1 mRNA
expression was 4.5 in non-LNM CRC (range: 3.21–10.52;Table 1 BRCA1 expression and relationship with
clinicopathological factors in CRC
Clinicopathological
factors
n BRCA1 expression P
value1Negative Positive
Sex
Male 61 27 34 0.205
Female 59 26 33
Age (yr)
≤ 60 80 40 40 0.236
> 60 40 16 24
Tumor size (cm)
≤ 5 84 40 44 0.134
> 5 36 18 18
Tumor location
Colon 45 20 25 0.508
Rectum 75 32 43
Tumor differentiation2
I-II 92 48 44 0.132
III-IV 28 10 18
Tumor status2
T1-2 42 21 21 0.384
T3-4 78 39 39
Lymph node metastasis2
N0 42 22 20 < 0.001
N1-2 78 66 12
TNM stage2
I-II 42 22 20 < 0.001
III-IV 78 67 11n = 60) and 2.6 in LNM CRC (range 1.3–10.16; n = 60).
Both ERCC1 and BRCA1 mRNA expression were down-
regulated in LNM CRC compared with non-LNM CRC.
Significant correlations between ERCC1 and BRCA1 ex-
pression levels (Spearman r= 0.516; P < 0.001) are shown in
Figure 1.
To compare the RT-PCR results with ERCC1 and
BRCA1 protein levels, we extended the experiments in the
same samples described above with western blot. Thirty
micrograms of total proteins from LNM CRC and non-
LNM CRC were analyzed using western blotting. Expres-
sion of ERCC1 and BRCA1 was dramatically higher in
non-LNM CRC compared with LNM CRC (P < 0.001). A
representative western blotting result is presented in
Figure 1A.Clinicopathological
factors
n ERCC1 expression P
value1Negative Positive
Sex
Male 61 29 32 0.325
Female 59 29 30
Age (yr)
≤ 60 80 38 42 0.367
> 60 40 20 20
Tumor size (cm)
≤ 5 84 42 42 0.157
> 5 36 16 20
Tumor location
Colon 45 19 26 0.521
Rectum 75 37 38
Tumor differentiation2
I-II 92 52 40 0.124
III-IV 28 12 16
Tumor status2
T1-2 42 20 22 0.404
T3-4 78 41 37
Lymph node metastasis2
N0 42 18 24 < 0.001
N1-2 78 70 8
TNM stage2
I-II 42 21 21 < 0.001
III-IV 78 65 13
1Statistical analysis was estimated with χ2 test, and P < 0.05 was considered
statistically significant;
2Grading of differentiation status and TNM classification for colorectal cancer
were based on the American Joint Committee on Cancer Cancer Staging
Manual (7th edition, 2009). The tumors were classified into two groups: well
differentiated (grades I and II) and poorly differentiated (grades III and IV).
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clinicopathological features and postoperative prognosis
of patients with CRC
To study the relationships between ERCC1 or BRCA1
expression and clinicopathological features, and to assess
whether ERCC1 or BRCA1 levels could predict clinical
outcomes for patients with CRC, an immunohistochem-
istry study was used to confirm the PCR results, using
the same samples.
Statistical analysis showed positive expressions of
ERCC1 and BRCA1 were significantly associated with
LNM, and advanced TNM stage (P < 0.001). However,
no significant correlations were observed between
ERCC1 or BRCA1 expression and other clinicopatholog-
ical parameters of sex, age, tumor size, tumor differenti-
ation and tumor location (Tables 1 and 2).
Furthermore, we have found that patients whose CRC
specimens were negative for ERCC1 or BRCA1 had signifi-
cantly poorer prognoses than those with ERCC1+/BRCA1+
CRC (Figure 2). The 5-year cumulative recurrence rate was
significantly higher for patients in the ERCC1+/BRCA1+Figure 2 Expression of ERCC1 and BRCA1 correlated with poor progngroup (P < 0.05). The 5-year estimated probability cumula-
tive survival rate was also different in both group pa-
tients with BRCA1– CRC or ERCC1– CRC than in the
ERCC1+/BRCA1+ group (P < 0.05). Univariate analyses
revealed that LNM, TNM stage, ERCC1 expression and
BRCA1 expression were related to recurrence and over-
all survival. In multivariate analysis, LNM, TNM stage,
ERCC1 expression and BRCA1 expression were also in-
dependent prognostic factors for recurrence and overall
survival (P < 0.05, Table 3).
Discussion
CRC is an aggressive cancer, with 300,000 newly diag-
nosed cases and 200,000 CRC-caused deaths each year
in Europe and the United States [13]. Biomarkers that
could help diagnose CRCs before metastases occur can
lead to earlier, more successful treatments. Moreover,
accurate biomarkers for metastases could aid clinicians
in identifying the most appropriate chemotherapies for
patients with CRC who have had resections; up to 50%
of patients who undergo potentially curative surgeriesosis in colorectal cancer patients.
Table 3 Univariate and multivariate analyses of recurrence and survival (Cox regression)
Variables Recurrence Survival
HR (95% CI) P value HR (95% CI) P value
Univariate analysis
Sex
Male/female 0.813 (0.479-1.518) 0.604 0.829 (0.424-1.618) 0.662
Age (yr)
≤ 60/> 60 1.506 (0.804-2.712) 0.163 1.822 (0.947-3.528) 0.065
Tumor size (cm)
≤ 5/> 5 0.876 (0.163-0.665) 0.687 0.880 (0.438-1.723) 0.704
Tumor location
Colon/rectum 0.812 (0.445-1.423) 0.518 0.904 (0.476-1.734) 0.778
Tumor differentiation
I-II/III-IV 1.212 (0.654-2.308) 0.501 1.151 (0.576-2.358) 0.650
Tumor status
T1-2/T3-4 0.866 (0.475-1.618) 0.687 1.020 (0.504-2.028) 0.904
Lymph node metastasis
N0/N1-2 2.707 (1.502-4.912) 0.011 2.812 (1.413-5.509) 0.012
TNM stage
I-II/III-IV 3.554 (1.932-6.526) <0.001 3.385 (1.677-6.843) <0.001
ERCC1 expression
Negative/positive 3.556 (1.919-6.932) <0.001 4.038 (1.913-8.712) <0.001
BRCA1 expression
Negative/positive 3.244 (1.191-7.012) <0.001 4.033 (1.906-8.512) <0.001
Multivariate analysis
LNM
N0/N1-2 0.210 (0.051-0.758) 0.018 0.196 (0.041-0.852) 0.028
TNM stage
I-II/III-IV 8.905 (2.072-38.190) 0.003 9.037 (1.703-48.105) 0.010
ERCC1 expression
Negative/positive 2.673 (1.134-6.011) 0.018 3.011 (1.236-7.95) 0.031
BRCA1 expression
Negative/positive 2.401 (1.115-5.722) 0.013 2.844 (1.106-7.44) 0.021
HR: Hazard ratio; CI: Confidence interval.
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disease [14].
More than 85% of CRCs have been attributed to envir-
onmental factors, which can produce adducts, damage
and strand breaks in DNA. Damaged DNA can be re-
moved and recovered by DNA-repairing enzymes, which
are critical for the genome protection and cancer pre-
vention [15,16]; the relationship between DNA repair
genes and various cancers has been widely studied [17].
Adjuvant therapy is important to the clinical outcomes
of the stage II–III cases that represent approximately
70% of CRC patients; adjuvant treatment following pri-
mary surgery could be improved by prognostic bio-
markers. In this study, we investigated whether ERCC1and BRCA1 could be such biomarkers and found that
their down-expression is associated with poor prognosis
in CRC.
ERCC1 is an endonuclease that helps perform NER of
DNA [18]. We found negative expression of ERCC1 to
correlate with LNM and advanced TNM stage, implying
that ERCC1 decreases CRC metastasis, and by extension,
that its reduced expression might be an early event in
colorectal carcinogenesis. Patients with CRC that ex-
presses negative ERCC1 have been shown to have high
cumulative recurrence and low cumulative survival. On
the other hand, the NER pathway is thought to repair
DNA damage cause by platinum agents; several studies
demonstrated an inverse relationship between impaired
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platinum drugs. Patients with CRC whose tumors show
low levels of ERCC1 gene amplification reportedly have
superior overall survival if treated with fluorouracil/
oxaliplatin. However, many factors affect metastasis.
ERCC1 could be restrained or promoted by other genes,
which could influence LNM somehow; this area is
already the subject of advanced research.
BRCA1 also has a role in DNA repair similar to that
of ERCC1. Variants of BRCA1 are markers for breast
and ovarian cancers, but it is unclear whether mutations
in this gene increase the risk of CRC. Our data show
that BRCA1 might be involved in CRC metastasis, as
with ERCC1, and therefore it is a potential biomarker
for CRC. However, changes in BRCA1 expression seem
to be less sensitive to early-stage disease, compared with
ERCC1, although changes in expressions of both pro-
teins appear to correlate with LNM. This correlation
between ERCC1 or BRCA1 expression and CRC metas-
tasis has been suggested recently [19,20], but no statis-
tical association could be established between reduced
expression of ERCC1 or BRCA1 and tumor stage and
lymph node involvement. Our data show relationships
between negative ERCC1 or BRCA1 expression and clin-
ical CRC LNM, implying that both ERCC1 and BRCA1
are involved in CRC metastasis, and that reduced
expression of these proteins are early events in colorec-
tal carcinogenesis.
Arguably, the most important relationship we found
was that between negative ERCC1 or BRCA1 expression
in CRC and poor patient survival. We found negative
ERCC1 or BRCA1 expression to correlate with LNM
and advanced TNM stage, which suggests that ERCC1
and/or BRCA1 affect CRC progression from localized to
LNM disease. In addition, patients with negative ERCC1
or BRCA1 expression in CRC have increased risk of
recurrence and significantly reduced overall survival
rates. Univariate and multivariate analyses indicate that
ERCC1 or BRCA1 expression could serve as independ-
ent prognostic factors for recurrence and overall survival
in patients with CRC.Conclusions
Our quantitative analysis of mRNA and protein expres-
sion showed ERCC1 and BRCA1 to be significantly
negatively expressed in LNM CRC. Further evaluation
using the same sample set suggests that ERCC1 and
BRCA1 are biomarkers for LNM and predictors of prog-
nosis in CRC.
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